NCT04281940已完成不适用
Chordal Repair for Transcatheter Mitral Valve Repair (TMVr)
Pipeline Medical8 个研究点 分布在 3 个国家目标入组 7 人开始时间: 2022年3月18日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 7
- 试验地点
- 8
- 主要终点
- Technical successful transcatheter implantation of the Chordal Repair System tethering the mitral leaflets to the ventricle
研究概览
简要总结
A multi-center evaluation of the Pipeline chordal repair system for treatment of clinically significant mitral regurgitation in subjects determined appropriate for mitral valve repair.
详细描述
The proposed study is a prospective, multi-center, interventional investigation enrolling up to 30 subjects in multiple sites in Latin America and Eastern Europe.
The primary objective of this study is to collect preliminary information on the performance and safety of the Pipeline Chordal Repair System in percutaneous reduction of significant mitral regurgitation (MR ≥ moderate) due to primary abnormality of the mitral apparatus [degenerative MR].
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 30 Years 至 85 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Presence of moderate to severe Mitral regurgitation as read on an echocardiographic study performed within 60 days prior to procedure.
- •Estimated post-ePTFE chordae tendineae implantation coaptation surface is adequate in the judgment of the operating physician and the patient eligibility committee.
- •Degenerative mitral valve disease.
- •Patients who have been evaluated and no contraindication has been found for open heart surgery OR candidates for mitral valve surgery who, according to current guidelines, are at elevated surgical risk AND for whom transcatheter therapy is deemed more appropriate than open heart surgery in the judgement of the Site Heart Team.
排除标准
- •Untreated clinically significant coronary artery disease requiring revascularization
- •Creatine Kinase-MB (CK-MB) obtained within prior 14 days > local laboratory Upper Limit of Normal (ULN)
- •Age <30/40 or > 85 years
- •Presence of any of the following:
- •Estimated pulmonary artery systolic pressure (PASP) > 70 mmHg assessed by site based on echocardiography or right heart catheterization
- •Hypertrophic cardiomyopathy, restrictive cardiomyopathy, constrictive pericarditis, ischemic or non-ischemic Functional mitral regurgitation or any other structural heart disease causing heart failure
- •Infiltrative cardiomyopathies (e.g., amyloidosis, hemochromatosis, sarcoidosis)
- •Hemodynamic instability requiring inotropic support or mechanical heart assistance
- •Hemodynamic instability defined as systolic pressure < 90 mmHg with or without afterload reduction, cardiogenic shock or the need for inotropic support or intra-aortic balloon pump or other hemodynamic support device
- •Physical evidence of right-sided congestive heart failure with echocardiographic evidence of moderate or severe right ventricular dysfunction
- •Left Ventricular Ejection Fraction (LVEF) is < 30% (within 90 days prior to subject enrollment, assessed by the site using any one of the following methods: echocardiography, contrast left ventriculography, gated blood pool scan or cardiac magnetic resonance imaging (MRI))
- •Mitral annular diameter >45mm in any dimension. Left Ventricular End Diastolic Diameter (LVEDD) > 65mm. Left Ventricular End Systolic Dimension (LVESD) > 55 mm assessed by site based on a transthoracic echocardiographic (TTE) obtained within 90 days prior to subject enrollment
- •Coronary artery bypass grafting (CABG) within 30 days prior to subject's consent
- •Percutaneous coronary intervention within 30 days prior to subject's consent
- •Tricuspid valve disease requiring surgery
- •Aortic valve disease requiring surgery or TAVI
- •Carotid surgery within 30 days prior to subject's consent
- •Implant of any Cardiac Resynchronization Therapy (CRT) or Cardiac Resynchronization Therapy with cardioverter-defibrillator (CRT-D) within the last 30 days prior to subject's consent
- •Need for emergent or urgent surgery for any reason or any planned cardiac surgery within the next 12 months
- •Prior mitral valve leaflet surgery or any currently implanted prosthetic mitral valve, or any prior transcatheter mitral valve procedure
- •Status 1 heart transplant or prior orthotopic heart transplantation
- •Chronic Kidney Disease with a baseline serum creatinine > 1.5mg/dL
- •Chronic Steroid Therapy
- •Cerebrovascular accident within 30 days prior to subject's consent
- •Severe symptomatic carotid stenosis (> 70 % via ultrasound)
- •Life expectancy < 12 months due to non-cardiac conditions
- •Active infections requiring current antibiotic therapy
- •Pregnant or planning pregnancy within next 12 months
- •Currently participating in an investigational drug or another device study
- •Severe organic lesions with mitral chords retraction, severely fibrotic and immobile leaflets, severely deformed subvalvular apparatus
- •Evolving endocarditis or active endocarditis in the last 3 months
- •Heavily calcified or dilated annulus or leaflets, mitral valve stenosis
- •Congenital malformation with limited valvular tissue
- •Patient requires mitral valve replacement
- •Previously implanted prosthetic mitral valve or annuloplasty ring/band
- •Evidence of LV or LA thrombus, vegetation or mass
- •Severe tricuspid regurgitation or severe RV dysfunction
- •Condition that prevents transfemoral access
- •Anatomical ineligibility to the investigational device
- •Known hypersensitivity or contraindication to procedural, post procedural medication (e.g., contrast solution, anticoagulation therapy) or hypersensitivity to nickel or titanium
结局指标
主要结局
Technical successful transcatheter implantation of the Chordal Repair System tethering the mitral leaflets to the ventricle
时间窗: Procedure
Technical Success
Safety at 30 days: freedom from death or intervention resulting from valve dysfunction or the implant procedure at 30 days.
时间窗: Procedure through 30 days post procedure
Primary Safety
Freedom from device-related Major Adverse Events (MAE), defined as a combined clinical endpoint of death, reoperation for failed surgical repair or replacement, non-elective cardiovascular surgery for adverse events, stroke or renal failure
时间窗: Procedure through 30 days post procedure
Primary Safety
Procedural success defined as the successful implant of the device resulting in MR severity of < moderate at 30 days as confirmed by echocardiography.
时间窗: Procedure through 30 days post procedure
Procedural Success
次要结局
未报告次要终点
研究者
研究点 (8)
Loading locations...
相似试验
尚未招募
不适用
To Evaluate the Efficacy and Safety of the Transfemoral Mitral Valve Repair System in the Treatment of Patients With Moderately Severe and Severe Functional Mitral Regurgitation(FMR) Who Remained Clinically Symptomatic After Guideline-directed Medical TreatmentMitral Valve InsufficiencyNCT05508438Pan Xiangbin140
Unknown
不适用
MitraClip for the Treatment of Moderate Functional Mitral Regurgitation: EVOLVE-MRMitral Valve Regurgitation Due to Cardiomyopathy (Disorder)Heart FailureMitral RegurgitationNCT03705312Montreal Heart Institute174
Unknown
不适用
ChordArt System for Mitral RegurgitationMitral Valve RepairMitral Valve InsufficiencyMitral RegurgitationNCT03581656CoreMedic GmbH5
Unknown
不适用
European FIH Study - NeoChord Transcatheter Mitral Repair System for Symptomatic Mitral RegurgitationMitral Valve InsufficiencyMitral Valve ProlapseDegenerativeHeart Valve DiseasesHeart DiseasesCardiovascular DiseasesMitral RegurgitationNCT05425628NeoChord30
Enrolling By Invitation
不适用
Safety and Effectiveness Study of Dragonfly System for Degenerative Mitral RegurgitationDegenerative Mitral Valve DiseaseNCT04734756Hangzhou Valgen Medtech Co., Ltd120